A Close Examination of Patient Experiences in Glioblastoma Multiforme Clinical Research
Part of paid clinical trials in San Francisco, California.
- Sponsor
- Power Life Sciences Inc.
- Study ID
- NCT05958485
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Glioblastoma Multiforme
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
Clinical research can sometimes favor certain demographic groups. Additionally, there is limited research that delves into the factors that influence participation in clinical study, both positive and negative. The goal is to identify the obstacles and challenges that prevent participation in glioblastoma multiforme clinical study, as well as the reasons for withdrawal or discontinuation. Insights gained from this study will ultimately benefit those with glioblastoma multiforme who may be invited to participate in clinical trial in the years to come.
Key Dates
- Start date
- Aug 31, 2024
- Status verified
- Jul 2023
- Primary completion
- Aug 31, 2025
- Completion
- Aug 31, 2026
Study Design
- Enrollment
- 500 participants (estimated)
Primary Outcome Measure
Rate of patients who decide to enroll in a glioblastoma multiforme clinical study. [ Time Frame: 3 months ]
Central Contacts
- Michael B Gill4159004227
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Power Life Sciences | San Francisco | California | 94107 |
Find similar trials in San Francisco, CA
Related Studies
- Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated GliomaPHASE1/PHASE2 · Recruiting · Neonc Technologies, Inc. · Los Angeles, California
- APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsPHASE2 · Recruiting · Apollomics Inc. · Los Angeles, California
- Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent GlioblastomaPHASE1/PHASE2 · Recruiting · Chirag G. Patil · Los Angeles, California
- A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBMPHASE1 · Recruiting · Boston Scientific Corporation · Birmingham, Alabama